Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
 - EconoTimes)
NEW YORK, Aug. 17, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocular Therapeutix, Inc. (NASDAQ:OCUL) who purchased shares between March 10, 2016 and July 11, 2017. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular’s re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular’s continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Shareholders have until September 5, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/ocular-therapeutix-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
